In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CASI Pharmaceuticals Inc.

www.casipharmaceuticals.com

Latest From CASI Pharmaceuticals Inc.

Asia Deal Watch: BeiGene And Celgene Exit Their Anti-PD-1 Collaboration

The Chinese firm regains all rights to tislelizumab ahead of the closing of Celgene’s merger with Bristol-Myers Squibb. BeiGene also forms cancer JV with US biotech SpringWorks.

Deals Asia Pacific

People Round-Up: Bhadauria Named As Amneal CSO

Amneal gets a new CSO, Acino restructures its board under a new chair, the AAM adds an assistant general counsel and the British Biosimilars Association names a vice-chair, as well as other people movements from around the generics, biosimilars and value-added medicines industries.

Appointments Strategy

Finance Watch: Lilly Completes Elanco Animal Health Spin-Out As New IPO Filings Keep Rising

Public Company Edition: Eli Lilly & Co. wasted no time spinning out its animal health business Elanco, which raised $1.5bn in its public debut. Also, as the biopharma IPO tally rises, Vivo Capital launches a new public life science company fund. Meanwhile, Concordia completes its recapitalization.

Financing Business Strategies

Lilly Reacquires Aurora Kinase Inhibitor Via AurKa Buy For $110m

Many Aurora kinase inhibitors have entered development, but while none have had a successful end, Lilly believes the specificity of AurKa's AK-01 will make it a safer drug. The asset fits well into Lilly's oncology strategy, which includes both targeted therapies and immuno-oncology drugs.

Deals Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • EntreMed Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • CASI Pharmaceuticals Inc.
  • Senior Management
  • Wei-Wu He, PhD, CEO
    George Chi, CFO
    Cynthia W Hu, COO
    Alexander A Zukwiski, MD, CMO
    James E Goldschmidt, PhD, SVP, Bus. Dev.
  • Contact Info
  • CASI Pharmaceuticals Inc.
    Phone: (240) 864-2600
    9620 Medical Center Dr.
    Ste. 300
    Rockville, MD 20850
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register